Dyslipidemias
Dyslipidemias
Explore linked clinical trials. Standard reference: MESH:M0010831428 results · Page 1 of 18
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Coronary Artery Calcium (CAC) Testing in Primary Care | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Not yet recruiting | Not applicable | 2026-10-09 | NCT07868809 | |
| A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Recruiting | Phase 2 | 2026-10-09 | NCT07799688 | |
| Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic disease | Not yet recruiting | Not applicable | 2026-10-09 | NCT07715890 | |
| Evaluation of an Integrated, Digital, Nurse-led, Remote Monitoring Care Pathway for Cardiovascular Risk Management | Arterial Occlusive Diseases, Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, hypertensive disorder, metabolic disease, vascular disorder | Recruiting | Not stated | 2026-10-09 | NCT07208331 | |
| An Efficacy and Safety Study of Akkermansia Muciniphila AKM Lab-01 in Hypercholesterolaemia | Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Active, not recruiting | Not applicable | 2026-10-09 | NCT06974266 | |
| Vitamin C Administration and Triglycerides Level in Critical Care Patients | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic disease | Recruiting | Not stated | 2026-10-09 | NCT06206759 | |
| Metabolic Effects of an Ophiocordyceps Sinensis- and CoQ10-Based Formulation in Mild-to-Moderate Hypercholesterolemia | Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Not yet recruiting | Not applicable | 2026-10-08 | NCT07852481 | |
| A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic disease | Recruiting | Phase 2 | 2026-10-08 | NCT07269210 | |
| Guideline Oriented Approach To Lipid Lowering In Asia-Pacific | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, acute coronary syndrome, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, heart disorder, hyperlipidemia, metabolic disease, myocardial ischemia, vascular disorder | Recruiting | Not applicable | 2026-10-08 | NCT05325034 | |
| Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, Skin Diseases, Metabolic, Skin and Connective Tissue Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hyperlipidemia, hypertriglyceridemia, lipodystrophy, metabolic disease, skin disorder | Active, not recruiting | Phase 2 | 2026-10-08 | NCT02262806 | |
| A Phase 1 Study of VELA-101 in Adult Participants | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Not yet recruiting | Phase 1 | 2026-10-07 | NCT07864311 | |
| Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, familial hypercholesterolemia, hereditary disease, homozygous familial hypercholesterolemia, hyperlipidemia, hyperlipoproteinemia, inborn errors of metabolism, metabolic disease | Recruiting | Phase 3 | 2026-10-06 | NCT07473843 | |
| Taining Golden Lake Comprehensive Chronic Disease Management Initiative | Atrophy, Chronic Disease, Disease Attributes, Dyslipidemias, Frailty, Lipid Metabolism Disorders, Neurologic Manifestations, Neuromuscular Manifestations, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Sarcopenia, Signs and Symptoms, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, metabolic disease, muscular atrophy, nervous system disorder, vascular disorder | Recruiting | Not stated | 2026-10-06 | NCT07308314 | |
| A Study to Evaluate COR-2003 as Monotherapy and Co-Administered With COR-1004 in Adult Volunteers | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Not yet recruiting | Phase 1 | 2026-10-05 | NCT07858019 | |
| A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia | Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Recruiting | Phase 3 | 2026-10-05 | NCT07619118 | |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, hyperlipidemia, metabolic disease, myocardial ischemia, vascular disorder | Recruiting | Phase 4 | 2026-10-05 | NCT06909565 | |
| PCSK9 Inhibitors in Hyperlipidemia and Atherosclerosis | Arterial Occlusive Diseases, Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Not yet recruiting | Not stated | 2026-10-02 | NCT07856264 | |
| Gauging Outcomes of Total Milk Ingestion on Lipid and gControl | Dyslipidemias, Insulin Resistance, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, cardiovascular disorder, glucose metabolism disease, heart disorder, hyperinsulinism, hyperlipidemia, metabolic disease | Recruiting | Not applicable | 2026-10-02 | NCT07087184 | |
| Causes and Natural History of Dyslipidemias | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Recruiting | Not stated | 2026-10-02 | NCT00353782 | |
| Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic disease | Active, not recruiting | Phase 3 | 2026-10-01 | NCT06822790 | |
| A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic disease | Not yet recruiting | Phase 2 | 2026-09-30 | NCT07848880 | |
| A Retrospective Real-World Cohort Study | Body Weight, Chronic Disease, Disease Attributes, Dyslipidemias, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lipid Metabolism Disorders, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, cardiovascular disorder, chronic renal failure syndrome, diabetes mellitus, endocrine system disorder, glucose metabolism disease, kidney disorder, kidney failure, metabolic disease, nutritional disorder, obesity disorder, overnutrition, prediabetes syndrome, type 2 diabetes mellitus, urinary system disorder | Active, not recruiting | Not stated | 2026-09-30 | NCT07781371 | |
| Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia | Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Active, not recruiting | Not stated | 2026-09-30 | NCT04579367 | |
| A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, hyperlipidemia, metabolic disease, myocardial ischemia, vascular disorder | Not yet recruiting | Phase 3 | 2026-09-29 | NCT07474649 | |
| Computerized Decision Support for Identification and Management of Familial Hypercholesterolemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, familial hypercholesterolemia, hereditary disease, hyperlipidemia, hyperlipoproteinemia, inborn errors of metabolism, metabolic disease | Recruiting | Not applicable | 2026-09-29 | NCT06743659 |